Industry News
-
Spur Therapeutics Reports Two-Year Follow-Up Data for AAV Gene Therapy FLT201 in Gaucher Disease
Feb 04 2026 -
Wugen’s Allogeneic CAR-T Therapy Receives FDA Breakthrough Therapy Designation for Relapsed or Refractory T-Cell ALL/LBL
Feb 04 2026 -
Atamyo Therapeutics Doses First Three Pediatric Patients with AAV Gene Therapy ATA-200 for LGMD-R5
Feb 04 2026 -
Affinia Therapeutics Secures FDA IND Clearance for AAV Gene Therapy AFTX-201 in BAG3 Dilated Cardiomyopathy
Feb 04 2026 -
New AAV gene therapy shows promise for treating nerve and heart defects in Friedreich’s ataxia
Feb 03 2026 -
AccurEdit Therapeutics Raises $75M Series A to Advance CRISPR Gene Editing Pipeline
Feb 03 2026 -
New Study Details Key Advances in Lentiviral Vector Engineering to Improve Safety, Targeting, and Therapeutic Durability in Gene Therapy
Feb 03 2026 -
Sangamo reports positive Phase 1/2 data for AAV gene therapy ST-920 in Fabry disease
Feb 03 2026 -
Moderna and Recordati Forge Strategic Alliance to Advance Breakthrough mRNA Therapy for Propionic Acidemia
Jan 30 2026